ZINGO Drug Patent Profile

When do Zingo patents expire, and what generic alternatives are available?

Zingo is a drug marketed by Powder Pharms and is included in one NDA. There are three patents protecting this drug.

This drug has seventeen patent family members in ten countries.

The generic ingredient in ZINGO is lidocaine hydrochloride. There are twenty-nine drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the lidocaine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zingo

A generic version of ZINGO was approved as lidocaine hydrochloride by WOCKHARDT BIO AG on November 18^th, 1982.

Summary for ZINGO

International Patents:	17
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	141
Patent Applications:	3,533
What excipients (inactive ingredients) are in ZINGO?	ZINGO excipients list
DailyMed Link:	ZINGO at DailyMed

Pharmacology for ZINGO

Drug Class	Amide Local Anesthetic Antiarrhythmic
Physiological Effect	Local Anesthesia

US Patents and Regulatory Information for ZINGO

ZINGO is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007		RX	No	No
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007		RX	No	No
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007		RX	No	No

Expired US Patents for ZINGO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007

International Patents for ZINGO

See the table below for patents covering ZINGO around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	066425	CASETE PARA PARTICULAS Y PROCESOS
Australia	674742
Greece	3022939
Hungary	9502911
Japan	2002179557	NEEDLELESS SYRINGE USING SUPERSONIC GAS FLOW FOR PARTICLE DELIVERY
United Kingdom	9326069

Market Dynamics and Financial Trajectory for ZINGO

Introduction

ZINGO, a topical local anesthetic, is used to manage the pain associated with venipuncture and peripheral intravenous cannulation, particularly in children. Here, we will delve into the market dynamics and financial trajectory of ZINGO, highlighting key factors that influence its market position and future prospects.

Product Overview

ZINGO is a needle-free, easy-to-use device that delivers a topical local anesthetic, lidocaine hydrochloride monohydrate, to numb the skin in as little as 1 to 3 minutes. This sterile, single-use device is powered by helium and does not require refrigeration, making it a convenient option for medical professionals[4].

Market Collaboration and Distribution

The market presence of ZINGO is bolstered by a collaboration between Marathon Pharmaceuticals, LLC, and Medline Industries, Inc. This partnership leverages Marathon's expertise in specialty drug development and manufacturing, while Medline's global distribution network ensures widespread availability of the product. This strategic collaboration enhances the market reach and accessibility of ZINGO[4].

Clinical Adoption and Usage

ZINGO is currently in use at several major children’s and academic hospitals. Its adoption is driven by its effectiveness in reducing venous access pain, a significant concern in pediatric care. The ease of use and quick analgesic effect make it a preferred choice among healthcare providers[4].

Market Demand and Growth Drivers

The demand for ZINGO is influenced by several factors, including the growing need for pain management solutions in pediatric care. As healthcare providers increasingly focus on patient comfort and pain reduction, products like ZINGO are likely to see increased adoption.

Financial Trajectory

The financial performance of ZINGO is tied to the broader pharmaceutical market trends. Here are some key financial aspects:

Revenue Streams

The revenue generated by ZINGO comes from its sales in hospitals and clinical settings. The collaboration with Medline Industries, a leading global distributor, helps in maximizing revenue through efficient distribution channels[4].

Cost Structure

The cost structure for ZINGO includes manufacturing costs, distribution expenses, and marketing expenditures. The partnership with Medline helps in optimizing these costs by leveraging their existing distribution infrastructure.

Market Valuation and Stock Performance

While specific financial data for ZINGO is not publicly available, the performance of its parent companies and the broader pharmaceutical sector can provide insights. For instance, drug companies often increase their advertising budgets when stock market returns are higher than expected, which can positively impact the market valuation of products like ZINGO[3].

Competitive Landscape

The market for topical local anesthetics is competitive, with several products available. However, ZINGO's unique features, such as its needle-free delivery system and quick analgesic effect, differentiate it from competitors. The strong distribution network and clinical adoption further solidify its market position[4].

Regulatory Environment

The regulatory environment plays a crucial role in the market dynamics of pharmaceutical products. ZINGO, being a FDA-approved device, must comply with stringent regulatory standards. Any changes in regulatory policies could impact its market trajectory, but as of now, it operates within a well-defined regulatory framework.

Future Prospects

The future prospects for ZINGO look promising due to several factors:

Growing Demand for Pain Management

The increasing focus on patient comfort and pain management in healthcare settings is likely to drive demand for ZINGO.

Expanding Distribution Channels

The collaboration with Medline Industries is expected to continue expanding the distribution channels for ZINGO, making it more accessible to a wider range of healthcare providers.

Innovative Marketing Strategies

Drug companies often use stock market performance to inform their advertising budgets. If Marathon Pharmaceuticals adopts similar strategies, it could enhance the marketing effectiveness for ZINGO, further boosting its market presence[3].

Challenges and Opportunities

While ZINGO has a strong market position, there are challenges and opportunities to consider:

Competition from Alternative Products

The market for topical anesthetics is competitive, and new products could challenge ZINGO's market share.

Regulatory Changes

Any changes in regulatory policies could impact the market dynamics of ZINGO.

Expanding into New Markets

There is an opportunity for ZINGO to expand into new markets, particularly in regions where pain management solutions are in high demand.

Key Takeaways

• ZINGO is a unique topical local anesthetic with a needle-free delivery system.
• The product benefits from a strong distribution partnership with Medline Industries.
• Growing demand for pain management solutions drives its market growth.
• Regulatory compliance and competitive landscape are key factors influencing its market dynamics.
• Future prospects are promising, with opportunities for expanded distribution and innovative marketing strategies.

Frequently Asked Questions (FAQs)

Q: What is ZINGO used for? A: ZINGO is used to manage the pain associated with venipuncture and peripheral intravenous cannulation, particularly in children.

Q: How does ZINGO work? A: ZINGO is a needle-free device that delivers a topical local anesthetic, lidocaine hydrochloride monohydrate, to numb the skin in as little as 1 to 3 minutes.

Q: Who are the key partners involved in the distribution of ZINGO? A: Marathon Pharmaceuticals, LLC, and Medline Industries, Inc. are the key partners involved in the distribution of ZINGO.

Q: What are the key factors driving the demand for ZINGO? A: The growing need for pain management solutions in pediatric care and the ease of use of the product are key factors driving the demand for ZINGO.

Q: How does the regulatory environment impact ZINGO? A: ZINGO must comply with stringent regulatory standards as an FDA-approved device. Any changes in regulatory policies could impact its market trajectory.

Cited Sources:

1. Persistence Market Research - Zinc Sulfate Market Size, Share & Forecast Analysis, 2031
2. Oregon Drug Use Review / Pharmacy & Therapeutics Committee - Pharmacy Utilization Summary Report: January 2019 - December 2019
3. University at Buffalo School of Management - How drug companies use the stock market to inform their advertising budgets
4. Biospace - Marathon Pharmaceuticals, LLC And Medline Industries, Inc. Enter Collaboration To Distribute Zingo Lidocaine Hydrochloride Monohydrate
5. Oliver Wyman - Improving Cell And Gene Therapy Infrastructure In Healthcare